Shiva Akbari-Birgani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shiva Akbari-Birgani has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Saeed Mohammadi
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications - Fatemeh Saghatchi
Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Gavazang, Zanjan, Iran
3 shared publications - Masoud Mohseni-Dargah
AMME School, Engineering Faculty The University of Sydney Sydney New South Wales Australia
3 shared publications Zahra Madadi
Department of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, 45137-66731, Iran
3 shared publicationsBabak Kaboudin
Center for Research in Basic Sciences, & Contemporary Technologies (IASBS), Zanjan, Iran
2 shared publications- Babak Kaboudin
Department of Chemistry Institute for Advanced Studies in Basic Sciences (IASBS) Zanjan Iran
2 shared publications
Latest Publications
- 16 January 2025
- Published by American Chemical Society (ACS) in ACS Applied Engineering Materials
- Vol. 3 (2) , 368-378
Chemo-Photothermal Therapy on Breast Cancer Cells in a 3D Coculture Hydrogel Model with In Situ Embedded Polydopamine Nanoparticle
- 16 January 2025
- Published by American Chemical Society (ACS) in ACS Applied Engineering Materials
- Vol. 3 (2) , 368-378
Chemo-Photothermal Therapy on Breast Cancer Cells in a 3D Coculture Hydrogel Model with In Situ Embedded Polydopamine Nanoparticle
- 3 January 2025
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 49 (5) , 1736-1744
A novel ligand system comprising N-heterocyclic carbene and Schiff base ligands: spectroscopic and electrochemical analysis, investigation of silver and gold complexation, and their biological effects
Schiff base condensation of 2,6-dimethylaniline with 3-(3-formyl-4-hydroxybenzyl)-3-methylimidazolium chloride, 1, which contains an aldehyde and methylimidazole chloride, allowed the preparation of compound 2. Using the templating effect of zinc ions, an ionic metal complex 3 was obtained, which served as a precursor to a new class of organometallic supramolecular architectures. This was achieved through the self-assembly of the two molecular units of 4 in the presence of silver oxide. This coordination-driven self-assembly process facilitated the cofacial arrangement of two Schiff base linkers. Both compound 5 and gold(I) complex 6 were characterized using multinuclear NMR spectroscopy and ESI-MS spectrometry techniques. The anticancer potentials of compounds 5 and 6 were evaluated. The low IC50 value indicates that compound 5 can efficiently induce cell death in breast cancer cells. The IC50 values of complexes 5 and 6 are 1.63 μM and 16.76 μM, respectively. Further studies have also demonstrated that complex 5 can eliminate cancer cells by halting the cell cycle in the G2 phase, leading to apoptotic cell death. Additionally, cytotoxicity evaluation using an MCF-7-derived organoid platform confirmed the ability of compound 5 to eliminate cancer cells, especially within the central region of the model.
- 3 January 2025
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 49 (5) , 1736-1744
A novel ligand system comprising N-heterocyclic carbene and Schiff base ligands: spectroscopic and electrochemical analysis, investigation of silver and gold complexation, and their biological effects
Schiff base condensation of 2,6-dimethylaniline with 3-(3-formyl-4-hydroxybenzyl)-3-methylimidazolium chloride, 1, which contains an aldehyde and methylimidazole chloride, allowed the preparation of compound 2. Using the templating effect of zinc ions, an ionic metal complex 3 was obtained, which served as a precursor to a new class of organometallic supramolecular architectures. This was achieved through the self-assembly of the two molecular units of 4 in the presence of silver oxide. This coordination-driven self-assembly process facilitated the cofacial arrangement of two Schiff base linkers. Both compound 5 and gold(I) complex 6 were characterized using multinuclear NMR spectroscopy and ESI-MS spectrometry techniques. The anticancer potentials of compounds 5 and 6 were evaluated. The low IC50 value indicates that compound 5 can efficiently induce cell death in breast cancer cells. The IC50 values of complexes 5 and 6 are 1.63 μM and 16.76 μM, respectively. Further studies have also demonstrated that complex 5 can eliminate cancer cells by halting the cell cycle in the G2 phase, leading to apoptotic cell death. Additionally, cytotoxicity evaluation using an MCF-7-derived organoid platform confirmed the ability of compound 5 to eliminate cancer cells, especially within the central region of the model.
- Open Access
- 15 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Aptamer-guided graphene oxide quantum dots for targeted suicide gene therapy in an organoid model of luminal breast cancer
Breast cancer is one of the most common cancers in women. One of the best therapeutic methods against breast cancer is gene therapy, while having an appropriate gene carrier is the biggest challenge of gene therapy. Hence, developing carriers with low cytotoxicity and high gene transfection efficiency, and preferentially with the selective function of gene delivery is a critical demand for this method. In the present study, we introduce a novel targeted carrier to deliver the inducible caspase-9 suicide gene (pLVSIN-iC9) into breast cancer cells. The carrier is composed of graphene oxide quantum dots decorated with polyethyleneimine, and S2.2; an aptamer with high affinity to MUC1 (GOQD-PEI/S2.2). Due to the overexpression of MUC1 in breast cancer cells, the designed GOQD-PEI/S2.2/pLVSIN-iC9 can selectively target cancer cells. Moreover, to better mimic solid tumor conditions, and to evaluate the selective effect of the GOQD-PEI/S2.2/pLVSIN-iC9, an organoid model derived from human dermal fibroblasts (HDF) and MCF-7 cells (coculture organoid) was generated and characterized. The results demonstrate that the coculture organoid model adapts the tissue structure of luminal breast cancer, as well. Therefore, the organoids were subjected to treatment with targeted gene therapy using GOQD-PEI/S2.2/pLVSIN-iC9. Our evidence supports the targeted killing effect of iC9 on the breast cancer cells of the organoids and suggests the good potential of the newly introduced carriers in targeted gene delivery.
- 15 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessAptamer-guided graphene oxide quantum dots for targeted suicide gene therapy in an organoid model of luminal breast cancer
Breast cancer is one of the most common cancers in women. One of the best therapeutic methods against breast cancer is gene therapy, while having an appropriate gene carrier is the biggest challenge of gene therapy. Hence, developing carriers with low cytotoxicity and high gene transfection efficiency, and preferentially with the selective function of gene delivery is a critical demand for this method. In the present study, we introduce a novel targeted carrier to deliver the inducible caspase-9 suicide gene (pLVSIN-iC9) into breast cancer cells. The carrier is composed of graphene oxide quantum dots decorated with polyethyleneimine, and S2.2; an aptamer with high affinity to MUC1 (GOQD-PEI/S2.2). Due to the overexpression of MUC1 in breast cancer cells, the designed GOQD-PEI/S2.2/pLVSIN-iC9 can selectively target cancer cells. Moreover, to better mimic solid tumor conditions, and to evaluate the selective effect of the GOQD-PEI/S2.2/pLVSIN-iC9, an organoid model derived from human dermal fibroblasts (HDF) and MCF-7 cells (coculture organoid) was generated and characterized. The results demonstrate that the coculture organoid model adapts the tissue structure of luminal breast cancer, as well. Therefore, the organoids were subjected to treatment with targeted gene therapy using GOQD-PEI/S2.2/pLVSIN-iC9. Our evidence supports the targeted killing effect of iC9 on the breast cancer cells of the organoids and suggests the good potential of the newly introduced carriers in targeted gene delivery.
- Open Access
- 2 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-17
Caspase-9 suppresses metastatic behavior of MDA-MB-231 cells in an adaptive organoid model
Caspase-9, a cysteine-aspartate protease traditionally associated with intrinsic apoptosis, has recently emerged as having non-apoptotic roles, including influencing cell migration—an aspect that has received limited attention in existing studies. In our investigation, we aimed to explore the impact of caspase-9 on the migration and invasion behaviors of MDA-MB-231, a triple-negative breast cancer (TNBC) cell line known for its metastatic properties. We established a stable cell line expressing an inducible caspase-9 (iC9) in MDA-MB-231 and assessed their metastatic behavior using both monolayer and the 3D organotypic model in co-culture with human Foreskin fibroblasts (HFF). Our findings revealed that caspase-9 had an inhibitory effect on migration and invasion in both models. In monolayer culture, caspase-9 effectively suppressed the migration and invasion of MDA-MB-231 cells, comparable to the anti-metastatic agent panitumumab (Pan). Notably, the combination of caspase-9 and Pan exhibited a significant additional effect in reducing metastatic behavior. Interestingly, caspase-9 demonstrated superior efficacy compared to Pan in the organotypic model. Molecular analysis showed down regulation of epithelial–mesenchymal transition and migratory markers, in caspase-9 activated cells. Additionally, flow cytometry analysis indicated a cell cycle arrest. Moreover, pre-treatment with activated caspase-9 sensitized cells to the chemotherapy of doxorubicin, thereby enhancing its effectiveness. In conclusion, the anti-metastatic potential of caspase-9 presents avenues for the development of novel therapeutic approaches for TNBC/metastatic breast cancer. Although more studies need to figure out the exact involving mechanisms behind this behavior.
- 2 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-17
Open AccessCaspase-9 suppresses metastatic behavior of MDA-MB-231 cells in an adaptive organoid model
Caspase-9, a cysteine-aspartate protease traditionally associated with intrinsic apoptosis, has recently emerged as having non-apoptotic roles, including influencing cell migration—an aspect that has received limited attention in existing studies. In our investigation, we aimed to explore the impact of caspase-9 on the migration and invasion behaviors of MDA-MB-231, a triple-negative breast cancer (TNBC) cell line known for its metastatic properties. We established a stable cell line expressing an inducible caspase-9 (iC9) in MDA-MB-231 and assessed their metastatic behavior using both monolayer and the 3D organotypic model in co-culture with human Foreskin fibroblasts (HFF). Our findings revealed that caspase-9 had an inhibitory effect on migration and invasion in both models. In monolayer culture, caspase-9 effectively suppressed the migration and invasion of MDA-MB-231 cells, comparable to the anti-metastatic agent panitumumab (Pan). Notably, the combination of caspase-9 and Pan exhibited a significant additional effect in reducing metastatic behavior. Interestingly, caspase-9 demonstrated superior efficacy compared to Pan in the organotypic model. Molecular analysis showed down regulation of epithelial–mesenchymal transition and migratory markers, in caspase-9 activated cells. Additionally, flow cytometry analysis indicated a cell cycle arrest. Moreover, pre-treatment with activated caspase-9 sensitized cells to the chemotherapy of doxorubicin, thereby enhancing its effectiveness. In conclusion, the anti-metastatic potential of caspase-9 presents avenues for the development of novel therapeutic approaches for TNBC/metastatic breast cancer. Although more studies need to figure out the exact involving mechanisms behind this behavior.
- 21 December 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 695, 149420
Mechanical effects modulate drug resistance in MCF-7-derived organoids: Insights into the wnt/β-catenin pathway
- 21 December 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 695, 149420
Mechanical effects modulate drug resistance in MCF-7-derived organoids: Insights into the wnt/β-catenin pathway
- 8 May 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 666, 107-114
Comparative evaluation of the therapeutic strategies using a minimal model of luminal-A breast cancer
- 8 May 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 666, 107-114
Comparative evaluation of the therapeutic strategies using a minimal model of luminal-A breast cancer
- Open Access
- 4 April 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (1) , 183-184
Correction: Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
- 4 April 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (1) , 183-184
Open AccessCorrection: Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
- 18 February 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (11) , 2435-2444
Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
Vimentin is a main type 3 intermediate filament protein. It seems that abnormal expression of vimentin is contributed to the appearance of the aggressive feature of cancer cells. So that it has been reported that malignancy and epithelial–mesenchymal transition in solid tumors, and poor clinical outcomes in patients with lymphocytic leukemia and acute myelocytic leukemia have been associated with the high expression of vimentin. Vimentin is a non-caspase substrate of caspase-9 although its cleavage by caspase-9 in biological processes has not been reported. In the present study, we sought to understand whether vimentin cleavage mediated by caspase-9 could reverse the malignancy in leukemic cells. Herein, to address the issue, we investigated vimentin changes in differentiation and took advantage of the inducible caspase-9 (iC9)/AP1903 system in human leukemic NB4 cells. Following the transfection and treatment of the cells using the iC9/AP1903 system, vimentin expression, cleavage, and subsequently, the cell invasion and the relevant markers such as CD44 and MMP-9 were evaluated. Our results revealed the downregulation and cleavage of vimentin which attenuates the malignant phenotype of the NB4 cells. Considering the favorable effect of this strategy in keeping down the malignant features of the leukemic cells, the effect of the iC9/AP1903 system in combination with all-trans-retinoic acid (ATRA) treatment was evaluated. The obtained data prove that iC9/AP1903 significantly makes the leukemic cells more sensitive to ATRA.
- 18 February 2023
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (11) , 2435-2444
Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells
Vimentin is a main type 3 intermediate filament protein. It seems that abnormal expression of vimentin is contributed to the appearance of the aggressive feature of cancer cells. So that it has been reported that malignancy and epithelial–mesenchymal transition in solid tumors, and poor clinical outcomes in patients with lymphocytic leukemia and acute myelocytic leukemia have been associated with the high expression of vimentin. Vimentin is a non-caspase substrate of caspase-9 although its cleavage by caspase-9 in biological processes has not been reported. In the present study, we sought to understand whether vimentin cleavage mediated by caspase-9 could reverse the malignancy in leukemic cells. Herein, to address the issue, we investigated vimentin changes in differentiation and took advantage of the inducible caspase-9 (iC9)/AP1903 system in human leukemic NB4 cells. Following the transfection and treatment of the cells using the iC9/AP1903 system, vimentin expression, cleavage, and subsequently, the cell invasion and the relevant markers such as CD44 and MMP-9 were evaluated. Our results revealed the downregulation and cleavage of vimentin which attenuates the malignant phenotype of the NB4 cells. Considering the favorable effect of this strategy in keeping down the malignant features of the leukemic cells, the effect of the iC9/AP1903 system in combination with all-trans-retinoic acid (ATRA) treatment was evaluated. The obtained data prove that iC9/AP1903 significantly makes the leukemic cells more sensitive to ATRA.
- 1 August 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 904, 174138
The effect of caspase-9 in the differentiation of SH-SY5Y cells
- 1 August 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 904, 174138
The effect of caspase-9 in the differentiation of SH-SY5Y cells
- 5 November 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (5) , 4066-4075
Synthesis, characterization, and in vitro evaluation of the starch‐based α‐amylase responsive hydrogels
Controlled‐release drug delivery systems are promising platforms in medicine. Among various types of material in drug delivery, hydrogels are interesting ones. They are water‐soluble and tissue compatible polymers with a high capacity to carry and release drugs in a controllable manner. In this study, we introduce the synthesis, characterization, and application of an α‐amylase responsive hydrogel in controlled drug delivery. The newly synthesized starch‐based hydrogels structurally characterized by means of Fourier‐transform infrared spectroscopy and scanning electron microscopy. A proapoptotic drug, doxorubicin, was loaded into the hydrogels and the controlled release of the drug was assessed in the presence of α‐amylase and ultimately it was evaluated to controlled‐drug release in vitro and subsequently in killing cancer cells. Our results highlight the effectiveness of temporal drug delivery using α‐amylase responsive hydrogels in killing cancer cells.
- 5 November 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (5) , 4066-4075
Synthesis, characterization, and in vitro evaluation of the starch‐based α‐amylase responsive hydrogels
Controlled‐release drug delivery systems are promising platforms in medicine. Among various types of material in drug delivery, hydrogels are interesting ones. They are water‐soluble and tissue compatible polymers with a high capacity to carry and release drugs in a controllable manner. In this study, we introduce the synthesis, characterization, and application of an α‐amylase responsive hydrogel in controlled drug delivery. The newly synthesized starch‐based hydrogels structurally characterized by means of Fourier‐transform infrared spectroscopy and scanning electron microscopy. A proapoptotic drug, doxorubicin, was loaded into the hydrogels and the controlled release of the drug was assessed in the presence of α‐amylase and ultimately it was evaluated to controlled‐drug release in vitro and subsequently in killing cancer cells. Our results highlight the effectiveness of temporal drug delivery using α‐amylase responsive hydrogels in killing cancer cells.